BC
CERE

Brookfield Corp’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Brookfield Corp’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-43,204
Closed -$1.27M – 763
2021
Q3 		$1.27M Buy
43,204
+13,690
+46% +$384K 0.01% 403
2021
Q2 		$756K Buy
29,514
+5,261
+22% +$75.3K ﹤0.01% 489
2021
Q1 		$333K Sell
24,253
-12,102
-33% -$177K ﹤0.01% 434
2020
Q4 		$603K Buy
+36,355
New +$472K ﹤0.01% 401

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return